COMPARE · Data as of August 24, 2026
ABBV vs NBIX
Verdict: Side-by-side breakdown using the Bull Rankings model. ABBV scored 63.6, NBIX scored 88.1 — NBIX leads.
Compare another set
ABBV
AbbVie Inc.
63.6
$264.52 · $467.4B
fundamentals as of
Score gap
24.5
NBIX leads
NBIX
Neurocrine Biosciences, Inc.
88.1
$153.04 · $15.6B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestNBIX22.3x
- Fastest growthNBIX+34.4%
- Highest qualityNBIX81 / 100
- Largest discount to fair valueNBIX-11%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ABBV
stronger →← stronger
NBIX
71
Qualityreturns · margins · balance sheet
81
66
Growthrevenue & earnings expansion
96
55
Valuevaluation vs sector peers
88
NBIX is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
ABBV
NBIX
$18.2bA-
FCF
$870mC+
+10.4%B
Rev
+34.4%A
—
D/E
0.12B+
74.5xC
P/E
22.3xB+
0.43A
PEG
0.45A
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ABBV
NBIX
31% above
Price vs fair valuelower is cheaper
11% below
~17%/yr
Growth the price implies10-yr FCF · lower = less priced in
~8%/yr
-35%
1-yr DCF upside
-6%
-24%
5-yr DCF upside
+12%
-3%
10-yr DCF upside
+46%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ABBV
Why this score
- Raising its dividend
NBIX
Why this score
- Durable high returns
- Diluting shareholders
The companies
ABBVAbbVie Inc.
Why now
Drug Manufacturers - General · market cap $467.4b. Trading near 52-week high of $267.47 — momentum setup, limited technical margin of safety. Revenue growing +10%, comfortably above the S&P median. PEG 0.43 — paying under fair value for the growth rate. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $276.59 (implying +5% upside).
Moat
Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. $467.4b market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trailing P/E 74.5x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. ROE -106% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
NBIXNeurocrine Biosciences, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $15.6b. 18% off the 52-week high of $186.12. Revenue growing +34% — in hypergrowth territory. PEG 0.45 — paying under fair value for the growth rate. 27 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $211.57 (implying +38% upside).
Moat
Net margin 21% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 123% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ABBV and NBIX diverge
On the headline score the gap is 24.5 points in favor of NBIX. The widest single difference is Value, where NBIX leads by 33.3 points.
- ValueABBV 54.7 · NBIX 88.0NBIX +33.3
- GrowthABBV 65.9 · NBIX 95.9NBIX +30.0
- QualityABBV 71.2 · NBIX 81.1NBIX +9.9
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.